Skip to main content

ANTICUERPOS MONOCLONALES INMUNOESTIMULANTES ANTI-PD-1 Y ANTI-CD137 EN COMBINACION CON TERAPIA CELULAR ADOPTIVA: EFECTOS SINERGICOS E INVESTIGACION TRASLACIONAL.

SAF2014-52361-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)

  • Azpilikueta, Arantza
  • Bolaños, Elixabet
  • Lang, Valerie
  • Labiano, Sara
  • Aznar, Maria A.
  • Etxeberria, Iñaki
  • Teijeira, Alvaro
  • Rodriguez-Ruiz, Maria E.
  • Perez-Gracia, Jose L.
  • Jure-Kunkel, Maria
  • Zapata, Juan M.
  • Rodriguez, Manuel S.
  • Melero, Ignacio
TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4–1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A20 or CYLD downregulated CD137-elicited ubiquitination of TRAF2 and TAK1 upon stimulation with agonist monoclonal antibodies. Moreover, overexpression of A20 or CYLD downregulated CD137-induced NF-κB activation in cultured cells and in gene-transferred hepatocytes in vivo, while silencing these deubiquitinases enhanced CD137 costimulation of primary human CD8 T cells. Therefore A20 and CYLD directly downregulate the signaling from a T and NK-cell costimulatory receptor under exploitation for cancer immunotherapy in clinical trials., MICINN (SAF2011-22831 and SAF2014-52361-R) (I.M), Departamento de Salud del Gobierno de Navarra, Redes temáticas de investigación cooperativa RETICC, European Commission VII Framework and Horizon 2020 programs (AICR and PROCROP), Fundación de la Asociación Española Contra el Cáncer (AECC), Fundación BBVA. MER-R receives support for a Rio Ortega Contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs

  • Zapata, Juan M.
  • Pérez-Chacón, Gema
  • Carr-Baena, Pablo
  • Martinez-Forero, Ivan
  • Azpilikueta, Arantza
  • Otano, Itziar
  • Melero, Ignacio
CD137 (4-1BB, Tnsfr9) is a member of the TNF-receptor (TNFR) superfamily without known intrinsic enzymatic activity in its cytoplasmic domain. Hence, akin to other members of the TNFR family, it relies on the TNFR-Associated-Factor (TRAF) family of adaptor proteins to build the CD137 signalosome for transducing signals into the cell. Thus, upon CD137 activation by binding of CD137L trimers or by crosslinking with agonist monoclonal antibodies, TRAF1, TRAF2, and TRAF3 are readily recruited to the cytoplasmic domain of CD137, likely as homo- and/or heterotrimers with different configurations, initiating the construction of the CD137 signalosome. The formation of TRAF2-RING dimers between TRAF2 molecules from contiguous trimers would help to establish a multimeric structure of TRAF-trimers that is probably essential for CD137 signaling. In addition, available studies have identified a large number of proteins that are recruited to CD137:TRAF complexes including ubiquitin ligases and proteases, kinases, and modulatory proteins. Working in a coordinated fashion, these CD137-signalosomes will ultimately promote CD137-mediated T cell proliferation and survival and will endow T cells with stronger effector functions. Current evidence allows to envision the molecular events that might take place in the early stages of CD137-signalosome formation, underscoring the key roles of TRAFs and of K63 and K48-ubiquitination of target proteins in the signaling process. Understanding the composition and fine regulation of CD137-signalosomes assembly and disassembly will be key to improve the therapeutic activities of chimeric antigen receptors (CARs) encompassing the CD137 cytoplasmic domain and a new generation of CD137 agonists for the treatment of cancer., Funding was from Instituto de Salud Carlos III (ISCIII) (PI16/00895 to JZ), Ministerio de Economía y Competitividad (MINECO) RTC-16-5118-1 to JZ and IM, SAF 2014-52361-R and SAF 2017-83267-C2-1R to IM; and Cancer Research Institute (CRI) CLIP Grant 2017, Asociación Española Contra el Cancer, Fundación BBVA and I-ON Network-BMS to IM. The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development (FEDER)., Peer reviewed